July 2023 in “Research Square (Research Square)” Using Cetirizine 1% cream daily can significantly improve hair growth and thickness in men with hair loss, and it's safe to use.
January 2025 in “Journal of Fungi” Advanced dermoscopy techniques improve diagnosis and treatment monitoring for Kerion celsi but don't guarantee full hair regrowth.
April 2024 in “JEADV clinical practice” Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
505 citations
,
October 2011 in “Journal of clinical oncology” MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.
April 2025 in “Biological and Clinical Sciences Research Journal” Nab-paclitaxel is as effective as cisplatin but safer for early-stage cervical cancer treatment.
January 2024 in “Wiadomości Lekarskie” Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.
October 2025 in “Australasian Journal of Dermatology” Bimekizumab effectively treated a man's chronic beard hair loss.
February 2014 in “Cancer Research” Recent findings advanced understanding of cancer mechanisms and potential treatments.
November 2025 in “Journal of Investigative Dermatology” Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
December 2017 in “British Journal of Dermatology” Targeted therapy for skin cancer is complex due to the role of the hedgehog pathway in both cancer and hair growth.
September 2023 in “Journal of The American Academy of Dermatology” Patients with skin cancer on the scalp and ear in Mexico have specific features and results from their treatments.
116 citations
,
December 2003 in “Acta Dermato Venereologica” Iressa often causes skin issues like acne and dryness in lung cancer patients.
2 citations
,
May 2023 in “Cancer medicine” KRT80 may worsen cancer by increasing growth and spread, but its full effects on treatment and outcomes need more research.
September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
37 citations
,
April 2010 in “FEBS Letters” The study concludes that the EDA2R gene is activated by p53 during chemotherapy but is not necessary for chemotherapy-induced hair loss.
November 2023 in “Anticancer Research” Using ultrasound may make cisplatin more effective against cervical cancer in mice.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
9 citations
,
December 2014 in “British Journal of Dermatology” Hedgehog pathway inhibitors used for skin cancer can cause significant hair loss, which may improve after stopping the medication.
MVP treatment is effective and safe for recurrent breast cancer.
June 2023 in “Deleted Journal” The document lists research on Pemetrexed and Cisplatin for lung cancer but doesn't give a final conclusion.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Ixekizumab effectively treated severe psoriasis and hair loss in a patient.
60 citations
,
June 1997 in “Drugs & Aging” Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.
January 2026 in “Human Mutation” T cell subsets are crucial in kidney cancer, and a new model predicts patient outcomes using key genes.
65 citations
,
October 2015 in “Acta Biomaterialia” The nano-carrier makes etoposide safer and more effective against lung cancer.
January 2025 in “Ege Tıp Bilimleri Dergisi” Radiotherapy affects mitochondrial-related genes in metastatic breast cancer cells.
9 citations
,
November 2023 in “Supportive Care in Cancer”
September 2023 in “SKIN The Journal of Cutaneous Medicine” Talquetamab may cause hair loss and skin issues.
April 2023 in “Journal of Investigative Dermatology” ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.
50 citations
,
June 1999 in “Annals of Oncology” Giving docetaxel weekly at 40 mg/m² is manageable and has low toxicity for cancer patients.
1 citations
,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.